Liver disease biomarkers (NAFLD/NASH)
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- UNIVERSITE D'ANGERS
French university combining advanced mathematics, optical materials, plant science, and transnational history of childhood and disability research.
“LITMUS investigated non-alcoholic fatty liver disease biomarker utility in steatohepatitis.”
FR11 projects - ALLERGAN LIMITED
UK arm of a global pharmaceutical company, contributing industry weight to European liver-disease biomarker and next-generation clinical trial methodology consortia.
“Partner in LITMUS, the flagship EU effort to validate non-invasive markers for non-alcoholic steatohepatitis.”
PrimaryUK3 projects - GILEAD SCIENCES INC
US biopharma giant bringing antiviral, hepatitis and liver-disease expertise to European consortia — industry partner for HBV cure, NAFLD biomarkers and immune therapy.
“Participant in LITMUS (2017-2024), a large IMI-style consortium on non-alcoholic steatohepatitis biomarker qualification.”
PrimaryUS3 projects